ArticleThoracic cancer2025
Chemoradiotherapy Combined With Modulated Electro-Hyperthermia (mEHT) Converts Initially Inoperable Esophageal Cancer to Operable Disease.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report demonstrated the effectiveness of combining chemoradiotherapy (CCRT) with modulated electro-hyperthermia (mEHT) in converting initially inoperable esophageal cancer into an operable condition. A 60-year-old male with stage IVB lower third esophageal squamous cell carcinoma (cT3N2M1) experienced significant tumor shrinkage (ypT2N0M0) and a notable metabolic response, which enabled successful surgical removal. This treatment approach highlights the potential of mEHT as a valuable addition to the comprehensive management of esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.